Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Mucin

Mucins (Mucin, MUC) are high molecular weight glycoproteins produced and secreted by epithelial cells, with mucus as their main component. Based on their functions, mucins can be divided into two categories: membrane-bound mucins and secreted mucins. Membrane-bound mucins include MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC14, MUC15, MUC16, MUC17, MUC20, MUC21, and MUC22, while secreted mucins include MUC2, MUC5AC, MUC5B, MUC6, MUC7, MUC8, MUC9, and MUC19. Abnormal mucin expression or function can lead to various diseases, including respiratory and gastrointestinal disorders, as well as certain types of cancer.

Gatipotuzumab
T783181264737-26-9
Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
  • $277
In Stock
Size
QTY
Clivatuzumab MMAE
T9901A-213
Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.
  • $1,690
In Stock
Size
QTY
Fudosteine
T148113189-98-5
Fudosteine is a novel mucoactive agent and a MUC5AC mucin hypersecretion inhibitor.
  • $30
In Stock
Size
QTY
Sofituzumab
T782851615692-28-8
Sofituzumab is a humanised monoclonal antibody targeting the MUC16 protein, commonly used in the synthetic ADC Sofituzumab vedotin, which can be used to treat ovarian cancer and pancreatic cancer.
  • $423
In Stock
Size
QTY
Minretumomab
T81793195189-17-4
Minretumomab (CC-49) is a mouse monoclonal antibody targeting TAG-72 (tumour-associated glycoprotein 72), optimised from the B72.3 antibody, and can be used for research into breast cancer, colon cancer, lung cancer, and pancreatic cancer.
  • $247
In Stock
Size
QTY
M0324
T9901A-749
M0324 is a novel MUC-1 conditional CD40 agonist composed of an anti-MUC-1 IgG and two identical CD40-targeting camelid VHH domains, designed to selectively activate immune cells in the context of tumor cells with high MUC-1 expression.
  • Inquiry Price
Size
QTY
Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA
T9901A-1107
Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the MC-Vc-PAB-DMEA-PEG2 connector and the DNA alkylator Duocarmycin SA. This compound is utilized in cancer research.
  • Inquiry Price
Size
QTY
TAB-004
T9901A-1037
TAB-004 is a human monoclonal antibody targeting MUC1. It specifically identifies the tMUC1 present in all major subtypes of breast cancer without affecting normal breast epithelial cells. Additionally, TAB-004 is applicable for research on triple-negative breast cancer (TNBC).
  • Inquiry Price
Size
QTY
BTH1704
T9901A-1057
BTH1704 is a human monoclonal antibody targeting MUC1. It facilitates the killing of iC3b-opsonized tumor cells by leukocytes triggered by PGG. BTH1704 is applicable in studies on pancreatic cancer and breast cancer.
  • Inquiry Price
Size
QTY
Fexlamose
T2061161285607-08-0
Fexlamose is an interventional nebulization solution with mucolytic properties, intended for research in chronic obstructive pulmonary disease (COPD).
  • Inquiry Price
10-14 weeks
Size
QTY
AR20.5
T9901A-991
AR20.5 is a human monoclonal antibody targeting MUC1. It enhances the number of activated CD8 T cells, CD3+CD4−CD8− (DN) T cells, and mature dendritic cells in mice with pancreatic tumors. AR20.5 is applicable for research into anti-pancreatic cancer immunity.
  • Inquiry Price
Size
QTY
Ubletamig
T9901A-8583008247-27-3
Ubletamig is a humanized IgG4κ monoclonal antibody that targets MUC16.
  • Inquiry Price
Size
QTY